This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Clinical Study to Assess the Influence of a Saw Palmetto Preparation in Patients With Benign Prostatic Hyperplasia (BPH) and Sexual Dysfunctions

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified November 2009 by Bioforce AG.
Recruitment status was:  Not yet recruiting
University of London
Information provided by:
Bioforce AG Identifier:
First received: November 25, 2009
Last updated: NA
Last verified: November 2009
History: No changes posted
Assessment in an open trial if a standardized saw palmetto preparation has a positive influence on sexual dysfunctions in patients with BPH and sexual dysfunctions.

Condition Intervention Phase
Sexual Dysfunctions in Men With Benign Prostatic Hyperplasia Drug: Saw palmetto berry extract Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Clinical Pilot Trial on the Influence of a Saw Palmetto Berry Preparation on Sexual Functions in Patients With Benign Prostatic Hyperplasia

Resource links provided by NLM:

Further study details as provided by Bioforce AG:

Primary Outcome Measures:
  • Change of the brief Sexual Function Inventory [ Time Frame: day 0 and day 56 ]

Secondary Outcome Measures:
  • change in IPSS change in Urolife Quality of Life questionnaire [ Time Frame: day 0 and day 56 ]

Estimated Enrollment: 50
Study Start Date: November 2009
Estimated Study Completion Date: September 2010
Estimated Primary Completion Date: September 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Saw palmetto berry extract
Saw palmetto berry extract, organic saw palmetto, ethanolic extract 96%
Drug: Saw palmetto berry extract
1x daily 1 capsule containing 320mg lipophilic extract
Other Name: Prostasan


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with BPH and sexual dysfunctions (erectile dysfunction or decrease in libido)
  • IPSS > 4
  • BSFI, sexual drive questions < 5

Exclusion Criteria:

  • Lack of libido which is due to a psychic disease or a depressive mood -Excessivly strong lack of libido in the judgement of the investigator within the last two months
  • Patients with severe vascular disorders (microangiopathies)
  • Patients with known neuropathies
  • Severe diabetes mellitus
  • Patients with hypertension who are for less than two months on a stable antihypertensive medication
  • Known bad compliance of the patient
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01021267

Contact: Andy Suter, M.Sc. 0041714546203

Dr. Eugen Riedi
Chur, Switzerland, 7000
Sponsors and Collaborators
Bioforce AG
University of London
Principal Investigator: Eugen Riedi, MD independent
  More Information

Responsible Party: Andy Suter, Head of Med. Dept., Bioforce AG Identifier: NCT01021267     History of Changes
Other Study ID Numbers: 920136
Study First Received: November 25, 2009
Last Updated: November 25, 2009

Keywords provided by Bioforce AG:
sexual dysfunctions
benign prostatic hyperplasia
saw palmetto

Additional relevant MeSH terms:
Prostatic Hyperplasia
Pathologic Processes
Prostatic Diseases
Genital Diseases, Male
Androgen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Estrogen Antagonists processed this record on September 21, 2017